加载中
NASDAQHealthcareBiotechnology
最新数据
US$3.59
−US$0.26 · -6.75%
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
收盘时
US$3.59
−US$0.26 · -6.75%
盘中时间采用ET。市场数据可能有所延迟。
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
日内区间
当前US$3.59
52周区间
当前US$3.59
盘中时间采用ET。市场数据可能有所延迟。
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
日内区间
当前US$3.59
52周区间
当前US$3.59
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 123.4万 USD | 13.5万 USD | — | — | — |
| 销货成本 | 5.3万 USD | — | — | — | — |
| 毛利 | 118.1万 USD | 13.5万 USD | — | — | — |
| 研究与开发 | 751.8万 USD | 910.5万 USD | 597.3万 USD | 250.3万 USD | 276.6万 USD |
| 销售、一般及管理费用 | 583.8万 USD | 887.2万 USD | 803.7万 USD | 691.6万 USD | 168.3万 USD |
| 营业费用 | 1335.6万 USD | 1797.7万 USD | 1421万 USD | 1160.9万 USD | 444.9万 USD |
| 利息收入 | 32.5万 USD | 10.1万 USD | — | 630 USD | — |
| 利息支出 | 32.9万 USD | 24.4万 USD | 108.1万 USD | 63万 USD | 21.2万 USD |
| 折旧和摊销 | 1.8万 USD | — | 1401万 USD | — | — |
| 营业利润 | −1217.5万 USD | −1784.2万 USD | −1421万 USD | −1160.9万 USD | −444.9万 USD |
| 净利润 | −1215万 USD | −2483万 USD | −2623.2万 USD | −1219万 USD | −459.6万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
